Intercell provides update on clinical trials for the patch-based travelers' diarrhoea vaccine.(Clinical report)

On 12 Dec 2010, Intercell AG announced preliminary clinical results on its investigational Travelers' Diarrhoea (TD) Vaccine Patch program and the decision not to pursue further the development of this vaccine candidate. The decision was made following the receipt of results of its randomized and placebo-controlled Phase III study (ELT301) with 2036 travelers from Europe to Mexico and Guatemala as well as the pilot efficacy Phase II trial (ELT209) with 723 travelers from Europe to India. Both trials were successfully conducted according to study design, met statistical targets of enrollment, participation follow-up, subject and site compliance, and produced a firm preliminary …